Melbourne, Australia. Tuesday 3rd October, 2006. Prima Biomed Limited (ASX: PRR) (‘Prima’) today announced the completion of a program for the scale up of manufacturing for CVacTM, the company’s cell therapy for ovarian cancer, in preparation for the next pivotal clinical trial.
